Avoid a discount: Secure your due diligence and Bpifrance financing
Blueprint 2026: Don’t let a technical blind spot break your lift. Join over 500 MedTech leaders.
The operational guide to anticipating France 2030 requirements and Series A/B bottlenecks.
📥 Receive the JuliaShift Blueprint (PDF)
Anticipate the locks of Series A and secure your France 2030 trajectory.
Successful MedTech fund-raising today depends as much on scientific quality as on the soundness of the project’s regulatory, industrial and sovereign trajectory. In the context of France 2030 and Bpifrance funding, the due diligence phase has become a strategic milestone, often underestimated by teams.
This MedTech 2026 Blueprint has been designed to help managers of e-health startups and scale-ups structure this preparation and secure their application before filing, based on concrete feedback and proven frameworks.
Why Bpifrance Due Diligence has become a critical step for MedTech startups
Bpifrance’ s due diligence is a decisive stage, where almost 30% of files stagnate due to a lack of structured preparation. The causes are rarely linked to the technology itself, but rather to peripheral issues that have become central to the evaluation: digital sovereignty, regulatory compliance, choice of healthcare data hosting, control of intellectual property or even industrialization trajectories.
That’s why we’ve condensed feedback from funded startups into this exclusive guide. Thanks to these resources, you don’t just apply: you secure every stage of your compliance to maximize your chances of obtaining financing.
What you'll find in the MedTech 2026 Blueprint
This guide has been designed as an operational tool to help you prepare for fund-raising in MedTech, particularly in the context of a Bpifrance or France 2030 application.
Here you’ll find
Exclusive checklist: the 50 critical control points used in the Bpifrance appraisal phase
Strategic roadmap: your action plan from 0 to 6 months before fund-raising
Real Benchmarks: analysis of three concrete MedTech startup trajectories, from Seed to Series A
Valuation: methods for calculating e-health revenue multiples
The aim is to provide you with a clear reading grid to identify your blind spots before they become blocking factors in the instruction phase.
A strategic guide designed for managers of MedTech and e-health scale-ups
Particularly adapted to the challenges of e-health, this Blueprint is aimed at managers of MedTech startups and scale-ups in the Seed, Series A or France 2030 filing phases. It is designed for teams who want to gain a clear view of the expectations of public and private funders, and structure their financing trajectory in a serious way.
Anticipating the requirements of France 2030, the IA Act and digital sovereignty
The evolution of the European regulatory framework, notably with the IA Act and the gradual implementation of the European Health Data Space (EHDS), is profoundly changing the evaluation criteria for MedTech projects. Digital sovereignty, healthcare data hosting and the ability to demonstrate a credible compliance trajectory are now at the heart of risk analysis by instructors and investors alike.
The MedTech 2026 Blueprint integrates these dimensions to help you structure a clear, robust and bankable trajectory.
Why prepare your fundraising with JuliaShift
JuliaShift supports MedTech projects that have to deal with highly constrained regulatory and operational environments. The approach is based on structuring the project’s overall trajectory, beyond the technological dimension alone. The analyses presented in these reports are based on real-life situations encountered during due diligence and financing applications.